Chlordiazepoxide (original) (raw)
Explore a selection of our essential drug information below, or:
Summary
Chlordiazepoxide is a benzodiazepine used to treat the withdrawal symptoms of acute alcoholism, to treat preoperative anxiety, and to treat anxiety over a short term period.
Brand Names
Chlorax, Librax
Generic Name
Chlordiazepoxide
DrugBank Accession Number
DB00475
Background
An anxiolytic benzodiazepine derivative with anticonvulsant, sedative, and amnesic properties. It has also been used in the symptomatic treatment of alcohol withdrawal.
Type
Small Molecule
Groups
Approved, Illicit, Investigational
Structure
Weight
Average: 299.755
Monoisotopic: 299.082539792
Chemical Formula
C16H14ClN3O
Synonyms
- 7-chloro-2-methylamino-5-phenyl-3H-1,4-benzodiazepin-4-oxide
- CDP
- Chloradiazepoxide
- Chlordiazepoxide
- Chlordiazepoxidum
- Clopoxide
- Clordiazepóxido
- Methaminodiazepoxide
Indication
Chlordiazepoxide is indicated for the management of anxiety disorders or for the short-term relief of symptoms of anxiety, withdrawal symptoms of acute alcoholism, and preoperative apprehension and anxiety.8
In combination with amitriptyline, chlordiazepoxide is indicated for the treatment of moderate to severe depression.7 In combination with clidinium, chlordiazepoxide is indicated to control emotional and somatic factors in gastrointestinal disorders, and is used as adjunctive therapy in the treatment of peptic ulcer, irritable bowel syndrome and acute enterocolitis.6
Reduce drug development failure rates Build, train, & validate machine-learning models with evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.
Associated Conditions
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
Pharmacodynamics
Chlordiazepoxide has antianxiety, sedative, appetite-stimulating and weak analgesic actions. The drug seems to block EEG arousal from stimulation in the brain stem reticular formation. The drug has been studied extensively in many species of animals and these studies are suggestive of action on the limbic system of the brain, which recent evidence indicates is involved in emotional responses. Hostile monkeys were made tame by oral drug doses which did not cause sedation. Chlordiazepoxide revealed a "taming" action with the elimination of fear and aggression. The taming effect of chlordiazepoxide was further demonstrated in rats made vicious by lesions in the septal area of the brain. The drug dosage which effectively blocked the vicious reaction was well below the dose which caused sedation in these animals.
Mechanism of action
Chlordiazepoxide binds to stereospecific benzodiazepine (BZD) binding sites on GABA (A) receptor complexes at several sites within the central nervous system, including the limbic system and reticular formation. This results in an increased binding of the inhibitory neurotransmitter GABA to the GABA(A) receptor. BZDs, therefore, enhance GABA-mediated chloride influx through GABA receptor channels, causing membrane hyperpolarization. The net neuro-inhibitory effects result in the observed sedative, hypnotic, anxiolytic, and muscle relaxant properties.
Target | Actions | Organism |
---|---|---|
AGABA(A) Receptor | positive allosteric modulator | Humans |
AGABA(A) Receptor Benzodiazepine Binding Site | ligand | Humans |
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Hepatic.
Route of elimination
Chlordiazepoxide is excreted in the urine, with 1% to 2% unchanged and 3% to 6% as conjugate.
Half-life
24-48 hours
Clearance
Not Available
Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
Toxicity
LD50=537 mg/kg (Orally in rats). Signs of overdose include respiratory depression, muscle weakness, somnolence (general depressed activity).
Pathways
Not Available
Not Available
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug | Interaction |
---|---|
Integrate drug-drug interactions in your software | |
1,2-Benzodiazepine | The risk or severity of CNS depression can be increased when Chlordiazepoxide is combined with 1,2-Benzodiazepine. |
Acetazolamide | The risk or severity of CNS depression can be increased when Chlordiazepoxide is combined with Acetazolamide. |
Acetophenazine | The risk or severity of CNS depression can be increased when Chlordiazepoxide is combined with Acetophenazine. |
Agomelatine | The risk or severity of CNS depression can be increased when Chlordiazepoxide is combined with Agomelatine. |
Alfentanil | The risk or severity of adverse effects can be increased when Alfentanil is combined with Chlordiazepoxide. |
Food Interactions
- Avoid alcohol.
- Take with or without food. The absorption is unaffected by food.
Drug product information from 10+ global regionsOur datasets provide approved product information including: dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
Ingredient | UNII | CAS | InChI Key |
---|---|---|---|
Chlordiazepoxide hydrochloride | MFM6K1XWDK | 438-41-5 | DMLFJMQTNDSRFU-UHFFFAOYSA-N |
Product Images
International/Other Brands
Angirex / Elenium (Polfa Tarchomin) / Helogaphen / Klopoxid (Nycomed) / Libritabs / Multum / Napoton / Radepur (AWD) / Risolid (Actavis) / Silibrin / Sonimen / Tropium
Brand Name Prescription Products
Generic Prescription Products
Mixture Products
ATC Codes
Drug Categories
- Adjuvants, Anesthesia
- Anti-Anxiety Agents
- Benzazepines
- Benzodiazepines and benzodiazepine derivatives
- Central Nervous System Agents
- Central Nervous System Depressants
- Cytochrome P-450 CYP3A Substrates
- Cytochrome P-450 CYP3A4 Substrates
- Cytochrome P-450 CYP3A4 Substrates (strength unknown)
- Cytochrome P-450 Substrates
- Cytosine Nucleotides
- GABA Agents
- GABA Modulators
- Heterocyclic Compounds, Fused-Ring
- Hypnotics and Sedatives
- Nervous System
- Neurotransmitter Agents
- Nucleic Acids, Nucleotides, and Nucleosides
- Nucleotides
- Psycholeptics
- Psychotropic Drugs
- Pyrimidine Nucleotides
- Pyrimidines
- Ribonucleotides
- Tranquilizing Agents
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as 1,4-benzodiazepines. These are organic compounds containing a benzene ring fused to a 1,4-azepine.
Kingdom
Super Class
Class
Sub Class
Direct Parent
Alternative Parents
Imidolactams / Benzene and substituted derivatives / Aryl chlorides / Nitrones / Propargyl-type 1,3-dipolar organic compounds / Carboxamidines / Azacyclic compounds / Organopnictogen compounds / Organochlorides / Organic zwitterions / Organic oxides / Hydrocarbon derivatives show 2 more
Substituents
1,4-benzodiazepine / Allyl-type 1,3-dipolar organic compound / Amidine / Aromatic heteropolycyclic compound / Aryl chloride / Aryl halide / Azacycle / Benzenoid / Carboxylic acid amidine / Hydrocarbon derivative / Imidolactam / Monocyclic benzene moiety / Nitrone / Organic 1,3-dipolar compound / Organic nitrogen compound / Organic oxide / Organic oxygen compound / Organic zwitterion / Organochloride / Organohalogen compound / Organonitrogen compound / Organopnictogen compound / Propargyl-type 1,3-dipolar organic compound show 13 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
organochlorine compound, secondary amino compound, N-oxide, benzodiazepine (CHEBI:3611)
Affected organisms
- Humans and other mammals
UNII
CAS number
58-25-3
InChI Key
ANTSCNMPPGJYLG-UHFFFAOYSA-N
InChI
InChI=1S/C16H14ClN3O/c1-18-15-10-20(21)16(11-5-3-2-4-6-11)13-9-12(17)7-8-14(13)19-15/h2-9H,10H2,1H3,(H,18,19)
IUPAC Name
7-chloro-2-(methylamino)-5-phenyl-3H-1,4-benzodiazepin-4-ium-4-olate
SMILES
CNC1=NC2=C(C=C(Cl)C=C2)C(C2=CC=CC=C2)=[N+]([O-])C1
Synthesis Reference
Sternbach, L.H.; US. Patent 2,893,992; July 7,1959; assigned to Hoffmann-LaRoche, Inc.
General References
- Skerritt JH, Johnston GA: Enhancement of GABA binding by benzodiazepines and related anxiolytics. Eur J Pharmacol. 1983 May 6;89(3-4):193-8. [Article]
- Oishi R, Nishibori M, Itoh Y, Saeki K: Diazepam-induced decrease in histamine turnover in mouse brain. Eur J Pharmacol. 1986 May 27;124(3):337-42. [Article]
- Earley JV, Fryer RI, Ning RY: Quinazolines and 1,4-benzodiazepines. LXXXIX: Haptens useful in benzodiazepine immunoassay development. J Pharm Sci. 1979 Jul;68(7):845-50. [Article]
- Olive G, Dreux C: [Pharmacologic bases of use of benzodiazepines in pereinatal medicine]. Arch Fr Pediatr. 1977 Jan;34(1):74-89. [Article]
- Vozeh S: [Pharmacokinetic of benzodiazepines in old age]. Schweiz Med Wochenschr. 1981 Nov 21;111(47):1789-93. [Article]
- FDA Approved Drug Products: Librax (chlordiazepoxide hydrochloride and clidinium bromide) capsules for oral use [Link]
- FDA Approved Drug Products: LIMBITROL (chlordiazepoxide and amitriptyline HCI) double strength tablets [Link]
- DailyMed Label: Chlordiazepoxide hydrochloride Oral Capsules [Link]
External Links
Human Metabolome Database
KEGG Drug
PubChem Compound
PubChem Substance
ChemSpider
BindingDB
RxNav
ChEBI
ChEMBL
ZINC
Therapeutic Targets Database
PharmGKB
RxList
Drugs.com
PDRhealth
Wikipedia
MSDS
Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more.
Manufacturers
- Valeant pharmaceuticals international
- Abbott laboratories pharmaceutical products div
- Rachelle laboratories inc
- Ascot hosp pharmaceuticals inc div travenol laboratories inc
- Barr laboratories inc
- John j ferrante
- Halsey drug co inc
- Impax laboratories inc
- Ivax pharmaceuticals inc sub teva pharmaceuticals usa
- Lederle laboratories div american cyanamid co
- Mm mast and co
- Mylan pharmaceuticals inc
- Parke davis div warner lambert co
- Pioneer pharmaceuticals inc
- Purepac pharmaceutical co
- Roxane laboratories inc
- Sandoz inc
- Superpharm corp
- Teva pharmaceuticals usa inc
- Usl pharma inc
- Vangard laboratories inc div midway medical co
- Watson laboratories inc
- West ward pharmaceutical corp
- Alra laboratories inc
Packagers
- A-S Medication Solutions LLC
- Barr Pharmaceuticals
- Cardinal Health
- Coupler Enterprises Inc.
- Direct Dispensing Inc.
- Dispensing Solutions
- Diversified Healthcare Services Inc.
- H and H Laboratories
- Heartland Repack Services LLC
- Innoviant Pharmacy Inc.
- Kaiser Foundation Hospital
- Legacy Pharmaceuticals Packaging LLC
- Liberty Pharmaceuticals
- Major Pharmaceuticals
- Merrell Pharmaceuticals Inc.
- Murfreesboro Pharmaceutical Nursing Supply
- Mylan
- Nucare Pharmaceuticals Inc.
- Palmetto Pharmaceuticals Inc.
- Par Pharmaceuticals
- Patheon Inc.
- PCA LLC
- PD-Rx Pharmaceuticals Inc.
- Pharmedix
- Physicians Total Care Inc.
- Prepackage Specialists
- Prepak Systems Inc.
- Qualitest
- Remedy Repack
- Sandhills Packaging Inc.
- Solco Healthcare US LLC
- Southwood Pharmaceuticals
- Stat Rx Usa
- UDL Laboratories
- Va Cmop Dallas
- Valeant Ltd.
Dosage Forms
Form | Route | Strength |
---|---|---|
Capsule | Oral | 10 mg |
Tablet, sugar coated | Oral | 5 mg |
Capsule | Oral | 25 mg |
Capsule | Oral | 5 mg |
Tablet | Oral | |
Tablet, film coated | Oral | |
Capsule | Oral | |
Capsule | Oral | 10 mg/1 |
Capsule | Oral | 25 mg/1 |
Capsule | Oral | 5 mg/1 |
Capsule, gelatin coated | Oral | |
Tablet, film coated | Oral | 5 mg |
Tablet | ||
Tablet, coated | Oral | |
Capsule | Oral | 10 mg / cap |
Capsule | Oral | 25 mg / cap |
Pill | ||
Tablet, sugar coated | Oral | 5 mg |
Tablet, film coated | ||
Pill | Oral | |
Tablet, coated | Oral | |
Tablet, sugar coated | Oral | |
Capsule, gelatin coated | Oral | 10 mg/1 |
Capsule, gelatin coated | Oral | 25 mg/1 |
Capsule, gelatin coated | Oral | 5 mg/1 |
Tablet, film coated | Oral | 25 MG |
Capsule | Oral | 5 mg / cap |
Capsule | Oral | |
Solution / drops |
Prices
Unit description | Cost | Unit |
---|---|---|
Librax 2.5-5 mg capsule | 6.5USD | capsule |
Librax capsule | 5.78USD | capsule |
Librium 25 mg capsule | 2.14USD | capsule |
Limbitrol DS 10-25 mg tablet | 1.93USD | tablet |
Librium 10 mg capsule | 1.61USD | capsule |
Librium 5 mg capsule | 0.84USD | capsule |
Chlordiazepoxide 25 mg capsule | 0.72USD | capsule |
ChlordiazePOXIDE HCl 25 mg capsule | 0.32USD | capsule |
ChlordiazePOXIDE HCl 10 mg capsule | 0.31USD | capsule |
ChlordiazePOXIDE HCl 5 mg capsule | 0.31USD | capsule |
Chlordiazepoxide 5 mg capsule | 0.2USD | capsule |
Apo-Chlordiazepoxide 25 mg Capsule | 0.17USD | capsule |
Chlordiazepoxide 10 mg capsule | 0.14USD | capsule |
Apo-Chlordiazepoxide 10 mg Capsule | 0.11USD | capsule |
Apo-Chlordiazepoxide 5 mg Capsule | 0.07USD | capsule |
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available
State
Solid
Experimental Properties
Property | Value | Source |
---|---|---|
melting point (°C) | 236-236.5 | Sternbach, L.H.; US. Patent 2,893,992; July 7,1959; assigned to Hoffmann-LaRoche, Inc. |
water solubility | 2000 mg/L | YALKOWSKY,SH & DANNENFELSER,RM (1992) |
logP | 2.44 | HANSCH,C ET AL. (1995) |
pKa | 4.8 | MERCK INDEX (1996) |
Predicted Properties
Property | Value | Source |
---|---|---|
Water Solubility | 0.0199 mg/mL | ALOGPS |
logP | 2.01 | ALOGPS |
logP | 0.19 | Chemaxon |
logS | -4.2 | ALOGPS |
pKa (Strongest Acidic) | -2.7 | Chemaxon |
pKa (Strongest Basic) | 7.06 | Chemaxon |
Physiological Charge | 1 | Chemaxon |
Hydrogen Acceptor Count | 3 | Chemaxon |
Hydrogen Donor Count | 1 | Chemaxon |
Polar Surface Area | 50.46 Å2 | Chemaxon |
Rotatable Bond Count | 1 | Chemaxon |
Refractivity | 87.34 m3·mol-1 | Chemaxon |
Polarizability | 31.22 Å3 | Chemaxon |
Number of Rings | 3 | Chemaxon |
Bioavailability | 1 | Chemaxon |
Rule of Five | Yes | Chemaxon |
Ghose Filter | Yes | Chemaxon |
Veber's Rule | No | Chemaxon |
MDDR-like Rule | No | Chemaxon |
Predicted ADMET Features
Property | Value | Probability |
---|---|---|
Human Intestinal Absorption | + | 1.0 |
Blood Brain Barrier | + | 0.9758 |
Caco-2 permeable | + | 0.5868 |
P-glycoprotein substrate | Substrate | 0.6705 |
P-glycoprotein inhibitor I | Non-inhibitor | 0.521 |
P-glycoprotein inhibitor II | Non-inhibitor | 0.7434 |
Renal organic cation transporter | Non-inhibitor | 0.5502 |
CYP450 2C9 substrate | Non-substrate | 0.6991 |
CYP450 2D6 substrate | Non-substrate | 0.9116 |
CYP450 3A4 substrate | Substrate | 0.7408 |
CYP450 1A2 substrate | Inhibitor | 0.7564 |
CYP450 2C9 inhibitor | Non-inhibitor | 0.6038 |
CYP450 2D6 inhibitor | Non-inhibitor | 0.7862 |
CYP450 2C19 inhibitor | Non-inhibitor | 0.5 |
CYP450 3A4 inhibitor | Inhibitor | 0.7067 |
CYP450 inhibitory promiscuity | High CYP Inhibitory Promiscuity | 0.6372 |
Ames test | Non AMES toxic | 0.593 |
Carcinogenicity | Non-carcinogens | 0.7108 |
Biodegradation | Not ready biodegradable | 1.0 |
Rat acute toxicity | 2.8520 LD50, mol/kg | Not applicable |
hERG inhibition (predictor I) | Weak inhibitor | 0.9198 |
hERG inhibition (predictor II) | Non-inhibitor | 0.8828 |
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)
Mass Spec (NIST)
Not Available
Spectra
Spectrum | Spectrum Type | Splash Key |
---|---|---|
Predicted GC-MS Spectrum - GC-MS | Predicted GC-MS | splash10-0ce9-3190000000-fd85fc0a63c0f6fa743a |
GC-MS Spectrum - CI-B | GC-MS | splash10-0udi-0079000000-a3045f81d776a5127fe9 |
GC-MS Spectrum - EI-B | GC-MS | splash10-001i-5590000000-a20477457b7e9f8a22ea |
LC-MS/MS Spectrum - LC-ESI-QTOF , positive | LC-MS/MS | splash10-001i-0090000000-a293b353926a16c4d11a |
MS/MS Spectrum - , positive | LC-MS/MS | splash10-004i-2590000000-965415c5fb9e79098c6d |
Predicted 1H NMR Spectrum | 1D NMR | Not Applicable |
Predicted 13C NMR Spectrum | 1D NMR | Not Applicable |
Chromatographic Properties
Collision Cross Sections (CCS)
Adduct | CCS Value (Å2) | Source type | Source |
---|---|---|---|
[M-H]- | 172.553974 | predicted | DarkChem Lite v0.1.0 |
[M-H]- | 165.91515 | predicted | DeepCCS 1.0 (2019) |
[M+H]+ | 173.028374 | predicted | DarkChem Lite v0.1.0 |
[M+H]+ | 168.27315 | predicted | DeepCCS 1.0 (2019) |
[M+Na]+ | 172.533774 | predicted | DarkChem Lite v0.1.0 |
[M+Na]+ | 174.87038 | predicted | DeepCCS 1.0 (2019) |
Targets
Build, predict & validate machine-learning modelsUse our structured and evidence-based datasets to unlock new insights and accelerate drug research.Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Kind
Protein group
Organism
Humans
Pharmacological action
Yes
Actions
Positive allosteric modulator
The GABA(A) receptor is pentameric (i.e. comprising 5 subunit proteins) and therefore has a multitude of potential isoforms. The above target is a collection of all possible GABA(A) subunits that may participate in the formation of the pentameric receptor and is not meant to imply direct a drug-protein interaction for each individual subunit.
General Function
Alpha subunit of the heteropentameric ligand-gated chloride channel gated by Gamma-aminobutyric acid (GABA), a major inhibitory neurotransmitter in the brain (PubMed:23909897, PubMed:25489750, PubMed:29950725, PubMed:30602789). GABA-gated chloride channels, also named GABA(A) receptors (GABAAR), consist of five subunits arranged around a central pore and contain GABA active binding site(s) located at the alpha and beta subunit interface(s) (PubMed:29950725, PubMed:30602789). When activated by GABA, GABAARs selectively allow the flow of chloride anions across the cell membrane down their electrochemical gradient (PubMed:23909897, PubMed:29950725, PubMed:30602789). Alpha-1/GABRA1-containing GABAARs are largely synaptic (By similarity). Chloride influx into the postsynaptic neuron following GABAAR opening decreases the neuron ability to generate a new action potential, thereby reducing nerve transmission (By similarity). GABAARs containing alpha-1 and beta-2 or -3 subunits exhibit synaptogenic activity; the gamma-2 subunit being necessary but not sufficient to induce rapid synaptic contacts formation (PubMed:23909897, PubMed:25489750). GABAARs function also as histamine receptor where histamine binds at the interface of two neighboring beta subunits and potentiates GABA response (By similarity). GABAARs containing alpha, beta and epsilon subunits also permit spontaneous chloride channel activity while preserving the structural information required for GABA-gated openings (By similarity). Alpha-1-mediated plasticity in the orbitofrontal cortex regulates context-dependent action selection (By similarity). Together with rho subunits, may also control neuronal and glial GABAergic transmission in the cerebellum (By similarity).
Specific Function
GABA-A receptor activity
Components:
References
- Zhu S, Noviello CM, Teng J, Walsh RM Jr, Kim JJ, Hibbs RE: Structure of a human synaptic GABAA receptor. Nature. 2018 Jul;559(7712):67-72. doi: 10.1038/s41586-018-0255-3. Epub 2018 Jun 27. [Article]
- Sigel E, Steinmann ME: Structure, function, and modulation of GABA(A) receptors. J Biol Chem. 2012 Nov 23;287(48):40224-31. doi: 10.1074/jbc.R112.386664. Epub 2012 Oct 4. [Article]
Kind
Protein group
Organism
Humans
Pharmacological action
Yes
Actions
Ligand
Benzodiazepines modulate GABA(A) function by binding at the interface between alpha (α) and gamma (γ) subunits. Of the 6 α-subunits, only 4 (α-1, -2, -3, and -5) participate in the formation of this binding site. The above target is a collection of all α- and γ-subunits that are known to participate in the formation of the benzodiazepine binding site.
General Function
Alpha subunit of the heteropentameric ligand-gated chloride channel gated by Gamma-aminobutyric acid (GABA), a major inhibitory neurotransmitter in the brain (PubMed:23909897, PubMed:25489750, PubMed:29950725, PubMed:30602789). GABA-gated chloride channels, also named GABA(A) receptors (GABAAR), consist of five subunits arranged around a central pore and contain GABA active binding site(s) located at the alpha and beta subunit interface(s) (PubMed:29950725, PubMed:30602789). When activated by GABA, GABAARs selectively allow the flow of chloride anions across the cell membrane down their electrochemical gradient (PubMed:23909897, PubMed:29950725, PubMed:30602789). Alpha-1/GABRA1-containing GABAARs are largely synaptic (By similarity). Chloride influx into the postsynaptic neuron following GABAAR opening decreases the neuron ability to generate a new action potential, thereby reducing nerve transmission (By similarity). GABAARs containing alpha-1 and beta-2 or -3 subunits exhibit synaptogenic activity; the gamma-2 subunit being necessary but not sufficient to induce rapid synaptic contacts formation (PubMed:23909897, PubMed:25489750). GABAARs function also as histamine receptor where histamine binds at the interface of two neighboring beta subunits and potentiates GABA response (By similarity). GABAARs containing alpha, beta and epsilon subunits also permit spontaneous chloride channel activity while preserving the structural information required for GABA-gated openings (By similarity). Alpha-1-mediated plasticity in the orbitofrontal cortex regulates context-dependent action selection (By similarity). Together with rho subunits, may also control neuronal and glial GABAergic transmission in the cerebellum (By similarity).
Specific Function
GABA-A receptor activity
Components:
References
- Sigel E, Steinmann ME: Structure, function, and modulation of GABA(A) receptors. J Biol Chem. 2012 Nov 23;287(48):40224-31. doi: 10.1074/jbc.R112.386664. Epub 2012 Oct 4. [Article]
- Zhu S, Noviello CM, Teng J, Walsh RM Jr, Kim JJ, Hibbs RE: Structure of a human synaptic GABAA receptor. Nature. 2018 Jul;559(7712):67-72. doi: 10.1038/s41586-018-0255-3. Epub 2018 Jun 27. [Article]
Enzymes
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
A cytochrome P450 monooxygenase involved in the metabolism of sterols, steroid hormones, retinoids and fatty acids (PubMed:10681376, PubMed:11093772, PubMed:11555828, PubMed:12865317, PubMed:14559847, PubMed:15373842, PubMed:15764715, PubMed:19965576, PubMed:20702771, PubMed:21490593, PubMed:21576599). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase). Catalyzes the hydroxylation of carbon-hydrogen bonds (PubMed:12865317, PubMed:14559847, PubMed:15373842, PubMed:15764715, PubMed:21490593, PubMed:21576599, PubMed:2732228). Exhibits high catalytic activity for the formation of hydroxyestrogens from estrone (E1) and 17beta-estradiol (E2), namely 2-hydroxy E1 and E2, as well as D-ring hydroxylated E1 and E2 at the C-16 position (PubMed:11555828, PubMed:12865317, PubMed:14559847). Plays a role in the metabolism of androgens, particularly in oxidative deactivation of testosterone (PubMed:15373842, PubMed:15764715, PubMed:22773874, PubMed:2732228). Metabolizes testosterone to less biologically active 2beta- and 6beta-hydroxytestosterones (PubMed:15373842, PubMed:15764715, PubMed:2732228). Contributes to the formation of hydroxycholesterols (oxysterols), particularly A-ring hydroxylated cholesterol at the C-4beta position, and side chain hydroxylated cholesterol at the C-25 position, likely contributing to cholesterol degradation and bile acid biosynthesis (PubMed:21576599). Catalyzes bisallylic hydroxylation of polyunsaturated fatty acids (PUFA) (PubMed:9435160). Catalyzes the epoxidation of double bonds of PUFA with a preference for the last double bond (PubMed:19965576). Metabolizes endocannabinoid arachidonoylethanolamide (anandamide) to 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acid ethanolamides (EpETrE-EAs), potentially modulating endocannabinoid system signaling (PubMed:20702771). Plays a role in the metabolism of retinoids. Displays high catalytic activity for oxidation of all-trans-retinol to all-trans-retinal, a rate-limiting step for the biosynthesis of all-trans-retinoic acid (atRA) (PubMed:10681376). Further metabolizes atRA toward 4-hydroxyretinoate and may play a role in hepatic atRA clearance (PubMed:11093772). Responsible for oxidative metabolism of xenobiotics. Acts as a 2-exo-monooxygenase for plant lipid 1,8-cineole (eucalyptol) (PubMed:11159812). Metabolizes the majority of the administered drugs. Catalyzes sulfoxidation of the anthelmintics albendazole and fenbendazole (PubMed:10759686). Hydroxylates antimalarial drug quinine (PubMed:8968357). Acts as a 1,4-cineole 2-exo-monooxygenase (PubMed:11695850). Also involved in vitamin D catabolism and calcium homeostasis. Catalyzes the inactivation of the active hormone calcitriol (1-alpha,25-dihydroxyvitamin D(3)) (PubMed:29461981).
Specific Function
1,8-cineole 2-exo-monooxygenase activity
Gene Name
CYP3A4
Uniprot ID
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
- Stolbach A, Paziana K, Heverling H, Pham P: A Review of the Toxicity of HIV Medications II: Interactions with Drugs and Complementary and Alternative Medicine Products. J Med Toxicol. 2015 Sep;11(3):326-41. doi: 10.1007/s13181-015-0465-0. [Article]
Drug created at June 13, 2005 13:24 / Updated at October 01, 2024 12:45